Association of WinRho® SDF (Rho(D) Immune Globulin (Human) with Intravascular Hemolysis (IVH) in the treatment of Immune Thrombocytopenic Purpura (ITP)

Pharmaforte updates healthcare professionals on the risk of IVH and its complications with WinRho® SDF when used in ITP. IVH can lead to severe anaemia and multi-organ failure including acute respiratory distress syndrome. From March 1995 to March 2009, 180 cases of IVH with WinRho® SDF have been reported worldwide. A disproportionate number of IVH cases were reported in patients with ITP secondary to hematological malignancies (leukemia or lymphoma) or active viral infections with HCV and EBV. Elderly patients with co-morbidities are more likely to experience renal and cardiovascular complications including fatal outcomes, from hemolysis. Physicians are encouraged to discuss the risks and benefits of WinRho® SDF and to alert patients about the signs and symptoms of IVH.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.